---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-023222"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:49:08.835941+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Vanda Pharmaceuticals General Counsel Timothy Williams resigns, effective Apr 10, 2026

## Summary
- Timothy Williams resigns as SVP, General Counsel and Secretary, effective April 10, 2026.
- No successor or interim replacement announced; search process not disclosed.
- Resignation is to pursue other endeavors; no conflict or disagreement noted.

## SEC filing metadata
- accession: 0001628280-26-023222
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828026023222/0001628280-26-023222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828026023222/vnda-20260329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-023222
- JSON: https://secwatch.observer/filing/0001628280-26-023222.json
- Plain text: https://secwatch.observer/filing/0001628280-26-023222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.